UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4635) 4635
Newsletter (313) 313
Book Chapter (42) 42
Newspaper Article (14) 14
Dissertation (9) 9
Conference Proceeding (7) 7
Publication (6) 6
Reference (4) 4
Magazine Article (3) 3
Streaming Video (3) 3
Book Review (2) 2
Book / eBook (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gefitinib (4802) 4802
science & technology (2964) 2964
life sciences & biomedicine (2762) 2762
humans (2629) 2629
oncology (1956) 1956
lung neoplasms - drug therapy (1399) 1399
female (1224) 1224
lung cancer (1183) 1183
carcinoma, non-small-cell lung - drug therapy (1161) 1161
cancer (1142) 1142
lung cancer, non-small cell (1107) 1107
epidermal growth factor (1068) 1068
male (1033) 1033
mutation (1025) 1025
quinazolines - therapeutic use (1012) 1012
middle aged (911) 911
antineoplastic agents - therapeutic use (903) 903
aged (860) 860
erlotinib (852) 852
lung neoplasms - genetics (764) 764
research (763) 763
care and treatment (742) 742
quinazolines - pharmacology (734) 734
cell line, tumor (719) 719
lung neoplasms - pathology (678) 678
chemotherapy (676) 676
tyrosine (661) 661
receptor, epidermal growth factor - antagonists & inhibitors (656) 656
non-small cell lung cancer (654) 654
egfr (648) 648
adult (612) 612
receptor, epidermal growth factor - genetics (611) 611
carcinoma, non-small-cell lung - genetics (602) 602
antineoplastic agents - pharmacology (590) 590
epidermal growth factor receptor (556) 556
respiratory tract diseases (550) 550
kinases (549) 549
epidermal growth factor receptors (548) 548
protein kinase inhibitors - therapeutic use (518) 518
carcinoma, non-small-cell lung - pathology (493) 493
treatment outcome (492) 492
animals (474) 474
quinazolines - administration & dosage (466) 466
genetic aspects (441) 441
pharmacology & pharmacy (441) 441
tumors (423) 423
analysis (421) 421
aged, 80 and over (398) 398
apoptosis (398) 398
drug therapy (397) 397
cancer therapies (395) 395
receptor, epidermal growth factor - metabolism (384) 384
protein kinase inhibitors - pharmacology (382) 382
quinazolines - adverse effects (376) 376
non-small cell lung carcinoma (369) 369
health aspects (356) 356
respiratory system (356) 356
neoplasms (353) 353
protein-tyrosine kinase (351) 351
adenocarcinoma - drug therapy (338) 338
erbb receptors - genetics (328) 328
proteins (324) 324
drug resistance (323) 323
metastasis (319) 319
erlotinib hydrochloride (318) 318
erbb receptors - antagonists & inhibitors (312) 312
mice (312) 312
signal transduction (309) 309
nsclc (297) 297
cell proliferation - drug effects (296) 296
drug resistance, neoplasm (293) 293
lung neoplasms - metabolism (290) 290
antineoplastic combined chemotherapy protocols - therapeutic use (286) 286
antineoplastic agents - adverse effects (285) 285
oncology, experimental (283) 283
lung neoplasms - mortality (276) 276
adenocarcinoma (272) 272
lung cancer, small cell (268) 268
prognosis (265) 265
apoptosis - drug effects (257) 257
medicine & public health (257) 257
hematology, oncology and palliative medicine (254) 254
patients (250) 250
clinical trials (246) 246
disease-free survival (246) 246
cell biology (236) 236
non-small-cell lung cancer (236) 236
signal transduction - drug effects (236) 236
carcinoma, non-small-cell lung - mortality (235) 235
retrospective studies (231) 231
gene expression (225) 225
biochemistry & molecular biology (222) 222
dosage and administration (221) 221
development and progression (220) 220
carcinoma, non-small-cell lung - metabolism (219) 219
phosphorylation (218) 218
medicine (215) 215
physical fitness (214) 214
drug resistance, neoplasm - genetics (213) 213
breast cancer (212) 212
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4812) 4812
Chinese (104) 104
Japanese (88) 88
Korean (42) 42
French (31) 31
Spanish (15) 15
German (11) 11
Czech (7) 7
Russian (6) 6
Portuguese (4) 4
Italian (3) 3
Polish (2) 2
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer chemotherapy and pharmacology, ISSN 1432-0843, 02/2019, Volume 83, Issue 5, pp. 849 - 858
Journal Article
Indian Journal of Medical Research, ISSN 0971-5916, 1/2019, Volume 150, Issue 1, pp. 67 - 72
Background & objectives: Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have been evaluated in patients with advanced... 
Immunology | Life Sciences & Biomedicine | Medicine, General & Internal | General & Internal Medicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Humans | Middle Aged | ErbB Receptors - genetics | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Erlotinib Hydrochloride - economics | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | ErbB Receptors - antagonists & inhibitors | Protein Kinase Inhibitors - economics | Carcinoma, Non-Small-Cell Lung - genetics | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Gefitinib - economics | Drug-Related Side Effects and Adverse Reactions - epidemiology | Carcinoma, Non-Small-Cell Lung - economics | Protein Kinase Inhibitors - administration & dosage | Mutation - drug effects | Cost-Benefit Analysis | Progression-Free Survival | Aged | Gefitinib - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Smoking | Carcinoma | Erlotinib | Patient outcomes | Comparative analysis | Gefitinib | Lung cancer, Non-small cell | Drug therapy | Cancer | Studies | Cellular biology | Lung cancer | Mutation | Females | Patients | Cancer therapies | Drug dosages | Age | Tumors | Index Medicus | non-small cell lung cancer | erlotinib | treatment response | gefitinib | pharmacoeconomic analysis | Original | Epidermal growth factor receptor inhibitors | Epidermal growth factor receptor inhibitors - erlotinib - gefitinib - non-small cell lung cancer - pharmacoeconomic analysis - treatment response
Journal Article
OncoTargets and therapy, ISSN 1178-6930, 07/2015, Volume 8, pp. 1603 - 1610
Journal Article
Annals of oncology, ISSN 0923-7534, 07/2004, Volume 15, Issue 7, pp. 1042 - 1047
Journal Article
Proteomics (Weinheim), ISSN 1615-9853, 08/2018, Volume 18, Issue 15, pp. e1700388 - n/a
Non‐small cell lung cancer (NSCLC) patients carrying EGFR activating mutations treated with gefitinib, a tyrosine kinase inhibitor, will develop drug... 
gefitinib resistance | ubiquitylome | non‐small cell lung cancer | proteome | non-small cell lung cancer | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Biochemical Research Methods | Science & Technology | Lung Neoplasms - drug therapy | Arachidonate 5-Lipoxygenase - genetics | Humans | Lung Neoplasms - metabolism | Ubiquitin - metabolism | Proteome - drug effects | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Autophagy | Endosomes - metabolism | Ubiquitination | Lysosomes - metabolism | HMGA2 Protein - metabolism | Mass Spectrometry | Arachidonate 5-Lipoxygenase - chemistry | HMGA2 Protein - genetics | Tumor Cells, Cultured | Gene Ontology | Carcinoma, Non-Small-Cell Lung - pathology | Gefitinib - pharmacology | Arachidonate 5-Lipoxygenase - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Proteome - analysis | Protein Kinase Inhibitors - pharmacology | Protein Processing, Post-Translational | Carcinoma, Non-Small-Cell Lung - drug therapy | Ubiquitin | Tyrosine | Chromosomal proteins | Lysine | Analysis | Lung cancer, Small cell | Drug resistance | Lung cancer, Non-small cell | Gefitinib | Target recognition | Epidermal growth factor receptors | Therapeutic applications | Lung cancer | Non-small cell lung carcinoma | Kinases | Proteins | Pathways | Mutation | Proteomes | Protein-tyrosine kinase | Phagocytosis | Cancer
Journal Article
Journal Article
Journal Article
Journal Article
Journal of translational medicine, ISSN 1479-5876, 05/2018, Volume 16, Issue 1, pp. 138 - 138
Background: The overall 5-year survival rate of lung cancer is about 15% even with therapeutic drugs like tyrosine kinase inhibitors. Ideal models are urgently... 
Signal pathway | Lung cancer | Patient-derived xenograft |